Literature DB >> 33290823

Gynecologic cancers and non-coding RNAs: Epigenetic regulators with emerging roles.

Zahra Sadat Razavi1, Vida Tajiknia2, Shahab Majidi3, Maryam Ghandali4, Hamid Reza Mirzaei5, Neda Rahimian6, Michael R Hamblin7, Hamed Mirzaei8.   

Abstract

Gynecologic cancers involve the female genital organs, such as the vulva, vagina, cervix, endometrium, ovaries, and fallopian tubes. The occurrence and frequency of gynecologic cancer depends on personal lifestyle, history of exposure to viruses or carcinogens, genetics, body shape, and geographical habitat. For a long time, research into the molecular biology of cancer was broadly restricted to protein-coding genes. Recently it has been realized that non-coding RNAs (ncRNA), including long noncoding RNAs (LncRNAs), microRNAs, circular RNAs and piRNAs (PIWI-interacting RNAs), can all play a role in the regulation of cellular function within gynecological cancer. It is now known that ncRNAs are able to play dual roles, i.e. can exert both oncogenic or tumor suppressive functions in gynecological cancer. Moreover, several clinical trials are underway looking at the biomarker and therapeutic roles of ncRNAs. These efforts may provide a new horizon for the diagnosis and treatment of gynecological cancer. Herein, we summarize some of the ncRNAs that have been shown to be important in gynecological cancers.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Circular RNAs; Endometrial cancer; Long noncoding RNAs; Micro-RNAs; Noncoding RNAs; Ovarian cancer; piRNAs

Year:  2020        PMID: 33290823     DOI: 10.1016/j.critrevonc.2020.103192

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  24 in total

Review 1.  Long non-coding RNA-based glycolysis-targeted cancer therapy: feasibility, progression and limitations.

Authors:  Xiaman Wang; Ying Shen; Rui Liu; Aili He
Journal:  Mol Biol Rep       Date:  2021-03-11       Impact factor: 2.316

Review 2.  Functions of lncRNA DUXAP8 in non-small cell lung cancer.

Authors:  Cui Wu; Wu Song; Zhongnan Wang; Bingmei Wang
Journal:  Mol Biol Rep       Date:  2022-01-15       Impact factor: 2.316

3.  Downregulation of DNMT3A Attenuates the Warburg Effect, Proliferation, and Invasion via Promoting the Inhibition of miR-603 on HK2 in Ovarian Cancer.

Authors:  Jiaojiao Lu; Shuai Zhen; Xiaoqian Tuo; Shixue Chang; Xiling Yang; Yuanyuan Zhou; Wei Chen; Le Zhao; Xu Li
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

4.  Cancer-Associated circRNA-miRNA-mRNA Regulatory Networks: A Meta-Analysis.

Authors:  Shaheerah Khan; Atimukta Jha; Amaresh C Panda; Anshuman Dixit
Journal:  Front Mol Biosci       Date:  2021-05-12

5.  MicroRNA-29a inhibits cell proliferation and arrests cell cycle by modulating p16 methylation in cervical cancer.

Authors:  Anjin Wang; Qiying Xu; Rengaowa Sha; Tonghui Bao; Xiaoli Xi; Guilan Guo
Journal:  Oncol Lett       Date:  2021-02-09       Impact factor: 2.967

6.  Constructe a novel 5 hypoxia genes signature for cervical cancer.

Authors:  Yang Yang; Yaling Li; Ruiqun Qi; Lan Zhang
Journal:  Cancer Cell Int       Date:  2021-07-03       Impact factor: 5.722

Review 7.  FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer.

Authors:  Cassie Liu; Carter J Barger; Adam R Karpf
Journal:  Cancers (Basel)       Date:  2021-06-19       Impact factor: 6.639

8.  Circular RNA: A novel type of biomarker for glioma (Review).

Authors:  Wei Sun; Huandi Zhou; Xuetao Han; Liubing Hou; Xiaoying Xue
Journal:  Mol Med Rep       Date:  2021-06-24       Impact factor: 2.952

9.  Exosomal circRNA as a novel potential therapeutic target for multiple myeloma-related myocardial damage.

Authors:  Runjie Sun; Wei Liu; Yangang Zhao; Haoyu Chen; Zhenzhen Wang; Yanyu Zhang; Xiaoqi Sun; Xing Cui
Journal:  Cancer Cell Int       Date:  2021-06-13       Impact factor: 5.722

10.  The potential oncogenic and MLN4924-resistant effects of CSN5 on cervical cancer cells.

Authors:  Huilin Zhang; Ping He; Qing Zhou; Yan Lu; Bingjian Lu
Journal:  Cancer Cell Int       Date:  2021-07-12       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.